Efectiveness of Acomplia in patients presenting with Type 2 Diabetes (this was the second phase of the RIO Europe Trial).
STUDY OBJECTIVE
To compare the effectiveness of Acomplia in patients presenting with Type 2 Diabetes (this was the second phase of the RIO Europe Trial).
DESIGN
This was a double-blind randomised study with a placebo control.
PATIENTS
1047 patients who were overweight or obese with a BMI in the range 27–40 kg/m2, suffering from Type 2 Diabetes. 692 patients completed the one-year study.
INTERVENTIONS
5mg or 20mg Acomplia was given orally once daily as a supplement to an advised mild exercise regime and a low-calorie diet designed to produce a net deficit of 600 kcal/day, monitoring weight, body measurements, blood pressure and blood chemistry from a baseline to values at the end of one year.
RESULTS
Weight loss was found to be significantly greater in both Acomplia groups than in the placebo group. There were few reported adverse side-effects, but more were reported in the higher dosage group which also had a higher discontinuation rate due to depressed mood disorders.
CONCLUSIONS
When combined with diet and exercise, Acomplia at 20 mg per day produced a clinically significant reduction in bodyweight and improved HbA1c and a number of cardiovascular and metabolic risk factors in overweight or obese patients suffering from Type 2 Diabetes.
|
| Giving up smoking |
|
|
 |
|
|
|
| Weight loss |
|
|
|
|
